Navigation Links
AnaptysBio Awarded U.S. Government Contract To Develop Anti-Ricin Antibodies
Date:5/16/2013

SAN DIEGO, May 16, 2013 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the receipt of a contract award from the U.S. government for the development of highly thermostable anti-ricin antibodies for biodefense applications.  Under the terms of AnaptysBio's contract with the Science and Technology Corporation, AnaptysBio will be responsible for delivering anti-ricin antibodies to the Edgewood Chemical and Biological Center (ECBC), an agency of the U.S. Army.  This contract is funded by the Defense Threat Reduction Agency (DTRA), and follows successful completion of multiple biodefense-related antibody programs by AnaptysBio in partnership with the Defense Advanced Research Projects Agency (DARPA). 

(Logo: http://photos.prnewswire.com/prnh/20111205/SF16052LOGO)  

The Company's antibody platform, known as SHM-XEL, is uniquely positioned to generate highly potent, functional antibodies for therapeutic and diagnostic uses.  Utilizing a proprietary antibody scaffold in conjunction with SHM-XEL, AnaptysBio has recently published the development of multiple full-length antibodies with unprecedented thermostability properties.   Extended stability at room temperature conditions minimizes the cold chain dependency of AnaptysBio's antibodies, which is a competitive advantage in the production, distribution and storage of therapeutic and diagnostic products.  

AnaptysBio's primary focus is to develop a pipeline of novel therapeutic antibodies for unmet medical needs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody drug conjugate applications.  In addition, AnaptysBio is exploring new opportunities for antibodies in diagnostics and veterinary uses.

"We are pleased to expand our relationship with the U.S. government to address emerging biodefense priorities," said Hamza Suria , president & chief executive officer of AnaptysBio. "The speed and technical advantages of our SHM-XEL technology platform continue to attract new partnerships.  Our platform's features have permitted AnaptysBio to rapidly develop a differentiated internal product pipeline against emerging targets of interest to pharma." 

About AnaptysBio

Founded in 2005, AnaptysBio, Inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization. AnaptysBio's proprietary SHM-XEL platform, which couples fully human antibody libraries with in vitro somatic hypermutation (SHM) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies.  By harnessing the natural mechanism of antibody maturation under controlled conditions, SHM-XEL allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. AnaptysBio has established broad intellectual property around the use of SHM and is currently building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. The Company has previously announced pharma partnerships with Merck, Roche, Novartis, Celgene, Gilead and DARPA.  Major investors in AnaptysBio include Alloy Ventures, Avalon Ventures, Frazier Healthcare Ventures and Novo A/S.  For more information, visit www.anaptysbio.com.


'/>"/>
SOURCE AnaptysBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AnaptysBio Develops Novel Antibody Scaffold With Extreme Thermostability
2. Anaptysbio Expands Leadership Team With Addition Of Dr. Andrew J. Mcknight
3. Aegis Awarded 2nd Patent for Fast Acting Migraine Nasal Spray Treatment
4. BidMed Awarded Equipment Liquidation and Related Services Agreement with the Premier Healthcare Alliance
5. Instrumentation Laboratory Awarded Massachusetts Life Sciences Center Tax Incentive
6. Dr. Isaac Eliaz Awarded Patent for Modified Citrus Pectin and Alginates
7. Creabilis Awarded Prestigious European Commission FP7 Grant to Further Develop its LSE Topical-by-Design Technology
8. Combat Medical Systems Awarded $86 Million DOD Contract
9. Remedium Technologies Inc. Awarded $500,000 Phase II NSF SBIR Grant to Test Sprayable Foam for Stopping Traumatic Bleeding
10. CCS Medical Awarded Medicare Contract
11. GE alliance awarded contract to design new plant-based manufacturing facility in Brazil
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Australie, le 24 février 2017 ITL Limited, ( ... diversifiée innovante, est ravie d,annoncer les excellents résultats semestriels ... période précédente correspondante. Une présentation complète « Résultats et mise ... consultée ici . Faits marquants ... 2,12 millions $ (Déc. 2015 : 1,04 million $ ; en hausse de 104 %) ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology drug ... has acquired exclusive worldwide rights to develop, manufacture ... inhibitor targeting hematological and solid tumors. ... and 2 clinical trials of Abexinostat in US, ... already been completed, demonstrating that Abexinostat is clinically ...
Breaking Medicine Technology:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The International ... 7th annual “Imagine Me Beyond What You See” body image mannequin art competition. Selected ... will be showcased and the winner revealed at the 31st annual iaedp Symposium, March ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, ... their Military Wedding Giveaway, with the winning couple announced on Feb. 14, 2017, ... generously donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which ... participating in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates ... a website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients ...
(Date:2/23/2017)... ... 23, 2017 , ... EBSCO Information Services (EBSCO) ... for Health and Care Excellence (NICE) framework. The agreement allows purchasers from ... to search, order and purchase medical and healthcare-related content through GOBI ®, ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... today that it will soon begin franchising throughout the U.S. starting this spring. ... help bring the practice of meditation mainstream. Current Meditation will be the first ...
Breaking Medicine News(10 mins):